Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress
نویسندگان
چکیده
With the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisininnaphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose (or a 1-day treatment). Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisininnaphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO the next generation ACT for the treatment of uncomplicated falciparum malaria.
منابع مشابه
Essai clinique randomisé comparant l’efficacité et la tolérance de la combinaison artémisinine–naphthoquine (Arco) et artéméther–luméfantrine (Coartem) dans le traitement du paludisme simple au Bénin
The Ministry of Health recommended in Benin, since 2004, artemisinin-based combination, artemether– lumtefantrine (Coartem), therapy for the treatment of uncomplicated malaria. To resolve the difficulties related to observance, we are interested in a new combination, artemisinin–naphthoquine (Arco). A study was conducted to assess and compare the efficacy and tolerability of the fixed combinati...
متن کاملArtemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria
BACKGROUND The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) for treating people with Plasmodium falciparum malaria. Five combinations are currently recommended, all administered over three days. Artemisinin-naphthoquine is a new combination developed in China, which is being marketed as a one-day treatment. Although shorter treatment courses may improve...
متن کاملArtemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial
BACKGROUND Artemisinin combination therapies (ACTs) with broad efficacy are needed where multiple Plasmodium species are transmitted, especially in children, who bear the brunt of infection in endemic areas. In Papua New Guinea (PNG), artemether-lumefantrine is the first-line treatment for uncomplicated malaria, but it has limited efficacy against P. vivax. Artemisinin-naphthoquine should have ...
متن کاملDevelopment of antimalarial drugs and their application in China: a historical review
This historical review covers antimalarials developed in China, which include artemisinin, artemether, artesunate, and dihydroartemisinin, as well as other synthetic drugs such as piperaquine, pyronaridine, benflumetol (lumefantrine), and naphthoquine. The curative effects of these antimalarials in the treatment of falciparum malaria, including chloroquine-resistant strain, are especially discu...
متن کاملInteractions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum
The 8-aminoquinoline tafenoquine (TFQ), a primaquine derivative, is currently in late-stage clinical development for the radical cure of P. vivax. Here drug interactions between TFQ and chloroquine and six artemisinin-combination therapy (ACT) partner drugs in P. falciparum asexual stages and gametocytes were investigated. TFQ was mostly synergistic with the ACT-partner drugs in asexual parasit...
متن کامل